Ocumetics Technology Corp. (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) on Monday reported encouraging six-month postoperative results from the first group of patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens. The outcomes exceed the company’s expectations, with all patients experiencing continuing vision improvements and a strong safety profile. Notably, patients reported life-changing improvements in quality of life, including the ability to read, drive, and live independently again.
The study enrolled patients with very poor vision, including one individual considered legally blind. At six months post-surgery, patients demonstrated improved vision and stable visual acuity. Anecdotally, all patients described the results as transformative. “What stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients’ quality of life,” said Dean Burns, President and CEO of Ocumetics. “Patients who entered this study with severely impaired vision are now reading, driving, and living independently again.”
The company is leveraging surgeon feedback and patient experience into ongoing product enhancements. Updated lens refinements are currently in manufacturing and testing, supporting the planned initiation of Group Two surgeries. “The measurable improvements in visual acuity and consistency we are seeing at six months give us tremendous confidence as we advance to the next phase of our clinical program,” added Burns. “We are not only validating our technology, we are demonstrating its real-world impact. Our focus now is to build on this success, further optimize performance, and bring this life changing solution to more patients.”
Ocumetics’ accommodating intraocular lens is designed to fit within the eye’s natural lens compartment and use the eye’s natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses. The company will host a webinar on April 22, 2026, at 4:00 PM ET to discuss the six-month results and updates on the FIH study. Registration is available at www.ocumetics.com/webinar.
The positive results validate the expected performance of Ocumetics’ inaugural accommodating intraocular lens and underscore the technology’s potential to transform vision correction. As the company advances toward Group Two surgeries, the momentum supports its mission of developing advanced vision correction solutions that enhance patient quality of life.
